Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
Author
Summary, in English
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the most efficacious drug for the treatment of Parkinson's disease (PD), but causes adverse effects that limit its utility. L-DOPA-induced dyskinesia (abnormal involuntary movements) is a significant clinical problem that attracts growing scientific interest. Current notions attribute the development of dyskinesia to two main factors, viz. the loss of nigrostriatal dopamine (DA) projections and the maladaptive changes produced by L-DOPA at sites postsynaptic to the nigrostriatal neuron. Basic research in the past 15 years has placed a lot of emphasis on the postsynaptic plasticity associated with dyskinesia, but recent experimental work shows that also some presynaptic factors, involving the regulation of L-DOPA/DA release and metabolism in the brain, may show plasticity during treatment. This review summarizes significant studies of L-DOPA-induced dyskinesia in patients and animal models, and outlines directions for future experiments addressing mechanisms of presynaptic plasticity. These investigations may uncover clues to the varying susceptibility to L-DOPA-induced dyskinesia among PD patients, paving the way for tailor-made treatments.
Department/s
Publishing year
2006
Language
English
Pages
381-392
Publication/Series
Journal of Neurochemistry
Volume
99
Issue
2
Full text
- Available as PDF - 336 kB
- Download statistics
Links
Document type
Journal article
Publisher
Wiley-Blackwell
Topic
- Neurosciences
Status
Published
Research group
- Basal Ganglia Pathophysiology
ISBN/ISSN/Other
- ISSN: 1471-4159